Iconovo AB (publ), which develops complete inhalation products for a global market, announce today that Gary Pitcairn will start working for the company in the role as Senior Scientific Advisor. Gary is a recognised expert in inhaled drug delivery and currently acts as the chairman of the Scientific Organising Committee of the annual Drug Delivery to the Lungs (DDL) international conference.
We are excited to announce that Gary Pitcairn will start working for Iconovo as Senior Scientific Advisor. In this role Gary will give advice to the project teams working on reformulations and support the efforts in bringing in new CDMO projects to Iconovo. Reformulating known APIs, including biologics, for inhalation and/or new indications require deep scientific knowledge. By bringing in Gary to Iconovo we see that we can better serve research-based customers.
Gary is a recognised expert in inhaled drug delivery, a senior leader, and has an outstanding network within pulmonary and nasal drug delivery business. He has a proven product development experience from big pharma, from preclinical through to late phase, including FDA interactions leading to NDA submissions. His technical expertise, senior scientific leadership, successful track record, and wide network will strengthen Iconovo’s offer within reformulated and novel inhaled medicines.
Gary received his PhD at University of Nottingham and has held roles as Head of Project Leadership within Respiratory at AstraZeneca, Senior Director within Respiratory Drug Delivery at Mylan, and has led the Research Inhalation Group at Pfizer. Gary’s most recent role was at Nanologica as CSO.
“I’m delighted to be joining the team at Iconovo. Developing new inhaled products is a challenging task, and Iconovo have both an impressive track record of device innovation and successful product development. I’m looking forward to working with clients, existing and new, to progress projects through early feasibility studies and on to demonstrating clinical proof of concept” says Gary Pitcairn.
Johan Wäborg, CEO
+46 707 78 51 71
Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).